ArticleJTO clinical and research reports2022

Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.

John M Varlotto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.